Fig. 1From: Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mLSelection and outcome of patients pathologically diagnosed with pretreatment PSA level ≥ 50 ng/mLBack to article page